At SpeeDx, we love pushing the boundaries of qPCR. With our innovation caps on, we’ve doubled your output with PlexPlus® technology. Take a look and see how it works.
SpeeDx ResistancePlus® diagnostics detect the infecting organism and antibiotic susceptibility or resistance markers – empowering clinicians to make informed patient treatment decisions.
Resistance Guided Therapy (RGT) uses advances in diagnostic technology to help clinicians choose the best targeted therapy for individual patients based on the resistance status of their infection.
Strategies for controlling many STIs are dependent on the availability of inexpensive yet highly effective antibiotics. As antimicrobial resistance rates rise in these infections it is even more important to use our limited antibiotics more wisely.
Guidelines for management of STIs caused by Mycoplasma genitalium and Neisseria gonorrhoeae increasingly recommend RGT to help:
Declining cure rates when employing detection-only practices for M. genitalium addressed with implementation of RGT, increasing cure rates for macrolide susceptible populations to 95% and total population cure rate over 92%.1
ResistancePlus® tests give your laboratory a competitive advantage. Now you can offer your clinicians more than just detection. The combination of resistance data with infection detection in a single-well test, enables RGT for improved patient management.
The PlexPCR® SARS-CoV-2 assay can help your laboratory regain efficiency through pandemic and post-pandemic testing. Based on our PlexZyme® technology, targeting highly conserved regions (RdRp/ORF1ab), and with automation compatibility – your laboratory can easily stay on top of COVID-19 testing and the supply challenges the pandemic has brought.
SARS-CoV-2 continues to mutate, giving rise to variants potentially impacting diagnostic testing and reporting. Reliable and accurate diagnostics are required by laboratories to save time, resources, and to have confidence in the data reported.
SpeeDx routinely monitors the ability of our PlexPCR® SARS-CoV-2 assay to detect emerging COVID variants. We have determined that our sequences match those seen in the recently reported Omicron variant, as well all other previously identified variants, to provide assurance that your laboratory can confidently report test results. Learn more.
Effective COVID-19 management is dependent on reliable and frequent testing. Disruptions in global manufacturing supply chains continue to limit availability of laboratory diagnostic kits, impacting local testing strategies.
SpeeDx utilises PlexZyme® technology, de-coupling the detection probe from the primer sequence to produce universal probes which can be used across our entire product portfolio. Our production can stockpile probes well in excess of ‘market demand’ to negate supply chain constraints. This enables us to readily ship kits in high volumes at all times – ensuring no interruptions to your daily laboratory testing. Learn more.
ResistancePlus® tests combine organism detection with genetic markers linked to antibiotic susceptibility or resistance. PlexPCR® tests combine multiple, clinically relevant infectious disease targets into a single test solution.
Single well qPCR test detecting Neisseria gonorrhoeae and markers linked to ciprofloxacin susceptibility
Single well qPCR test detecting and differentiating HSV-1, HSV-2, VZV & Treponema pallidum (Syphilis)
Single well qPCR test detecting Mycoplasma genitalium and markers linked to macrolide resistance
Single well qPCR test detecting and differentiating HSV-1, HSV-2 and VZV
2 well qPCR test detecting and differentiating 11 respiratory viruses
Cartridge-based test detecting M. genitalium and macrolide resistance markers
Workflow Solutions |
Resistance Guided Therapy |
Technology |
Collaborations |
Publications & Media |
Conferences & Events |
Deliver innovative clinical diagnostics to improve patient outcomes
PlexPCR® Flu/RSV/SARS-CoV-2 | Upfront diagnosis | Combat seasonal testing surges with ease. SpeeDx Pty. Ltd., have expanded their ...
06 September, 2024Inaugural RespiV PlexPlus®* product showcases advantages SpeeDx unveils a new innovative spin on qPCR technology that doubles the ...
09 April, 2024Our mission is to deliver innovative clinical diagnostics to improve patient outcomes. Meet the SpeeDx Team, learn about our key collaborations and partnerships, and join our passion to change the face of diagnostics.
References:
1Read TRH et al. Clinical Infectious Diseases 2019; 68(4):554-560
2Harris SR et al. Lancet Infect Dis Published online May 15th 2018
3Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015
4Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5
5Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7);1–19